![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
RETRACTION article
Front. Oncol. , 27 November 2023
Sec. Cancer Genetics
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1322464
This article is part of the Research Topic Genomics and Epigenomics of Cancer Immunotherapy: Challenges and Clinical Implications View all 22 articles
This article is a retraction of:
RETRACTED: Long Non-Coding RNA ELFN1-AS1 Promoted Colon Cancer Cell Growth and Migration via the miR-191-5p/Special AT-Rich Sequence-Binding Protein 1 Axis
A Retraction of the Original Research Article
Long non-coding RNA ELFN1-AS1 promoted colon cancer cell growth and migration via the miR-191-5p/special AT-rich sequence-binding protein 1 axis
by Du Y, Hou Y, Shi Y, Liu J and Li T (2021) Long Non-Coding RNA ELFN1-AS1 Promoted Colon Cancer Cell Growth and Migration via the miR-191-5p/Special AT-Rich Sequence-Binding Protein 1 Axis. Front. Oncol. 10:588360. doi: 10.3389/fonc.2020.588360
Please find the retraction statement below:
Following publication, concerns were raised regarding the integrity of the images in the published figures.
Following the provision of raw data by the authors, the Chief Editor concluded that the article’s conclusions and assertions were not sufficiently supported by the findings from the material provided; therefore, the article has been retracted.
This retraction was approved by the Chief Editor of Frontiers in Oncology and the Chief Executive Editor of Frontiers.
Citation: Frontiers Editorial Office (2023) Retraction: Long non-coding RNA ELFN1-AS1 promoted colon cancer cell growth and migration via the miR-191-5p/special AT-rich sequence-binding protein 1 axis. Front. Oncol. 13:1322464. doi: 10.3389/fonc.2023.1322464
Received: 16 October 2023; Accepted: 16 October 2023;
Published: 27 November 2023.
Approved by:
Sharon R. Pine, University of Colorado Anschutz Medical Campus, United StatesCopyright © 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, cmVzZWFyY2guaW50ZWdyaXR5QGZyb250aWVyc2luLm9yZw==
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.